

January 28, 2020

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on January 28, 2020 along with Unaudited Financial Results (Standalone & Consolidated) and Press Release for the quarter and nine months ended December 31, 2019

Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, *inter alia*, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2019. In this regard, kindly find enclosed the following:

1. A copy of Unaudited Standalone and Consolidated Financial Results along with Limited Review Report issued by the Statutory Auditors of the Company for the quarter and nine months ended December 31, 2019.
2. A copy of Press Release and Investors Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2019.

The Board Meeting commenced at 11:15 A.M. and concluded at 1:00 P.M.

Thanking you,

Yours faithfully,
For **Sequent Scientific Limited**



Krunal Shah
Company Secretary & Compliance Officer
Encl.: A/a



SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7,Road No. 22, Wagle Industrial Area, Thane (W), Mumbai – 400604, India

Tel: +91 22 41114777 | FAX: +91-22-41114754 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
SeQuent Scientific Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of SeQuent Scientific Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2019 and year to date from April 01, 2019 to December 31, 2019 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the entities mentioned in Annexure I to the Statement
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The accompanying Statement includes unaudited interim financial results and other unaudited financial information of twelve subsidiaries, whose interim financial results reflect Group's share of total revenues of Rs. 19,357 lakhs and Rs. 50,857 lakhs, Group's share of total net profit after tax of Rs. 1,125 lakhs and Rs. 3,596 lakhs, Group's share of total comprehensive income of Rs. 1,270 lakhs and Rs. 4,263 lakhs for the quarter ended December 31, 2019 and for the period from April 01, 2019 to December 31, 2019, respectively, as considered in the Statement, which have been reviewed by their respective independent auditors. The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.
7. The accompanying Statement of unaudited consolidated financial results include unaudited interim financial results and other unaudited financial information in respect of eight subsidiaries, which have not been reviewed by their auditors, whose interim financial results reflect Group's share of total revenues of Rs. 52 lakhs and Rs. 164 lakhs, Group's share of total net loss after tax of Rs. 85 lakhs and Rs. 581 lakhs, Group's share of total comprehensive loss of Rs. 141 lakhs and Rs. 587 lakhs, for the quarter ended December 31, 2019 and for the period from April 01, 2019 to December 31, 2019, respectively, as considered in the Statement. These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.
- Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.
8. The comparative Ind AS financial information of the Group for the corresponding quarter and period ended December 31, 2018, included in these consolidated Ind AS financial results, were reviewed by the predecessor auditor and the Ind AS consolidated financial statements of the Group for the year ended March 31, 2019, was audited by predecessor auditor who expressed an unmodified conclusion/opinion on that consolidated financial information and that consolidated financial statements on February 01, 2019 and May 14, 2019 respectively.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003



per Vikas Kumar Pansari

Partner

Membership No.: 093649

UDIN: 20093649AAAAAF5128



Mumbai

January 28, 2020

Annexure I to Auditor's Report

Name of the Entity

- | | | |
|----|--|-------------------------|
| 1. | SeQuent Research Limited | Wholly Owned Subsidiary |
| 2. | Elysian Life Sciences Private Limited | Wholly Owned Subsidiary |
| 3. | SeQuent Pharmaceuticals Private Limited (Upto July 26, 2019) | Wholly Owned Subsidiary |
| 4. | SeQuent Antibiotics Private Limited (Upto July 26, 2019) | Wholly Owned Subsidiary |
| 5. | Alivira Animal Health Limited, India | Wholly Owned Subsidiary |

Including it's following subsidiary:

6. Alivira Animal Health Limited, Ireland

Including its following subsidiaries and sub subsidiaries:

7. Alivira Animal Health Australia Pty Limited
8. Alivira France
9. Alivira Italia SRL
10. Alivira UA Limited, Ireland (Upto August 18, 2019)
11. Alivira Saude brasil participacoes Ltda
12. Bremer Pharma GmbH
13. Comercial Vila Veterinaria De Lleida S.L.
14. Evance Saude Animal Ltda
15. Fendigo BV
16. Fendigo SA
17. Interchange Veterinária Indústria E Comércio Ltda.
18. Laboratorios Karizoo, S.A.
19. Laboratorios Karizoo, S.A. DE C.V. (Mexico)
20. N-Vet AB
21. Phytotherapic Solutions S.L.
22. Provet Veteriner Ürünleri San. Ve Tic. A. Ş.
23. Topkim Topkapi İlaç premiks Sanayi Ve Ticaret A.Ş.
24. Vila Viña Participacions S.L.



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2019

(₹ in Lakhs)

	Particulars	3 months ended 31-Dec-2019	Preceding 3 months ended 30-Sep-2019	Corresponding 3 months ended in the previous year 31-Dec-2018	Year to date figure for the current period ended 31-Dec-2019	Year to date figure for the previous period ended 31-Dec-2018	Previous year ended 31-Mar-2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	31,642.10	28,422.30	27,052.80	87,866.10	75,740.40	1,03,930.70
II	Other income	98.20	597.00	198.80	826.40	624.50	867.20
III	Total income (I+II)	31,740.30	29,019.30	27,251.60	88,692.50	76,364.90	1,04,797.90
IV	Expenses						
(a)	Cost of materials consumed	13,218.40	12,253.80	9,872.50	37,474.90	30,165.10	45,387.10
(b)	Purchases of stock-in-trade	2,865.10	1,831.30	3,313.90	6,923.80	10,126.20	11,664.40
(c)	Changes in inventories of finished goods, stock-in-trade and work-in-progress	93.40	990.90	938.90	1,165.50	(408.60)	(2,750.30)
(d)	Employee benefits expense	4,280.10	4,079.90	3,688.20	12,331.40	10,647.90	14,594.90
(e)	Finance costs	960.20	783.70	834.50	2,638.40	2,390.00	3,280.20
(f)	Depreciation and amortisation expense	1,305.40	1,246.40	1,115.80	3,753.00	3,099.80	4,192.00
(g)	Other expenses	6,186.60	5,550.50	5,670.80	17,411.90	16,616.30	22,541.20
	Total expenses	28,909.20	26,736.50	25,434.60	81,698.90	72,636.70	98,909.50
V	Profit before tax (III-IV)	2,831.10	2,282.80	1,817.00	6,993.60	3,728.20	5,888.40
VI	Tax expense						
(a)	Current tax	591.00	470.50	596.60	1,452.60	1,286.90	1,419.90
(b)	Deferred tax (Refer note 8)	(153.00)	(622.90)	985.10	(817.20)	525.30	598.30
(c)	Current tax of prior period reversed (Refer note 8)	(12.70)	(11.40)	(1,321.80)	(23.80)	(1,639.00)	(1,817.50)
	Total tax expenses	425.30	(163.80)	259.90	611.60	173.20	200.70
VII	Profit after tax (V-VI)	2,405.80	2,446.60	1,557.10	6,382.00	3,555.00	5,687.70
VIII	Other comprehensive income / (expenses)						
	Items that will not be reclassified to profit or loss						
(a)	Re-measurement gain / (loss) on defined benefits plans	(1.20)	(1.30)	3.20	(2.90)	25.40	(43.30)
(b)	Fair value gain / (loss) from investment in equity instruments	2,133.10	(3,423.40)	911.30	(3,571.50)	(5,192.10)	(4,217.50)
(c)	Income tax relating to items that will not be reclassified to profit or loss	0.50	1.10	-	1.60	-	-
	Items that may be reclassified to profit or loss						
(a)	Exchange differences on translation of foreign operations	86.70	872.00	(1,113.97)	701.70	(43.91)	546.51
(b)	Exchange differences on net investment in foreign operations	2.40	30.40	262.61	(29.30)	(371.22)	(1,651.12)
(c)	Income tax relating to items that may be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income / (expenses) (net of tax)	2,221.50	(2,521.20)	63.14	(2,900.40)	(5,581.83)	(5,365.41)
IX	Total comprehensive income / (expenses) (VII+VIII)	4,627.30	(74.60)	1,620.24	3,481.60	(2,026.83)	322.29
	Profit attributable to:						
-	Owners of the Company	2,030.50	2,128.80	1,302.50	5,305.00	3,153.60	4,866.00
-	Non-controlling interest	375.30	317.80	254.60	1,077.00	401.40	821.70
	Other comprehensive income / (expenses) attributable to:						
-	Owners of the Company	2,243.30	(2,572.40)	118.74	(2,904.30)	(5,416.13)	(5,071.65)
-	Non-controlling interest	(21.80)	51.20	(55.60)	3.90	(165.70)	(293.76)
	Total comprehensive income / (expenses) attributable to:						
-	Owners of the Company	4,273.80	(443.60)	1,421.24	2,400.70	(2,262.53)	(205.65)
-	Non-controlling interest	353.50	369.00	199.00	1,080.90	235.70	527.94
X	Equity share capital (face value of ₹ 2 each)	4,967.40	4,937.40	4,874.70	4,967.40	4,874.70	4,937.40
XI	Other equity						65,731.80
XII	Earnings per equity share: (face value of ₹ 2 each) (not annualised)						
(1)	Basic (in ₹)	0.83	0.88	0.54	2.18	1.30	2.00
(2)	Diluted (in ₹)	0.83	0.87	0.53	2.17	1.29	1.99
	See accompanying notes to the unaudited consolidated financial results						

**SIGNED FOR IDENTIFICATION
BY**

✓

S R B C & CO LLP
MUMBAI



Sequent

Proven Ability in Life Sciences
SEQUENT SCIENTIFIC LIMITED

Notes:

1. The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28 January 2020. The statutory auditors have carried limited review of the above results.

2. The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.

3. Information on Standalone Results:

(₹ in Lakhs)

Particulars	3 months ended 31-Dec-2019	Preceding 3 months ended 30-Sep-2019	Corresponding 3 months ended in the previous year 31-Dec-2018	Year to date figure for the current period ended 31-Dec-2019	Year to date figure for the previous period ended 31-Dec-2018	Previous year ended 31-Mar-2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	6,179.90	5,152.00	4,814.30	16,503.90	11,066.90	16,626.00
Profit before tax	469.20	664.20	86.60	1,275.70	619.80	620.30
Profit after tax	291.83	1,018.41	86.60	1,452.54	619.80	758.64
Total comprehensive income / (expenses)	2,425.73	(2,404.49)	999.60	(2,116.56)	(4,567.20)	(3,454.46)

4. Effective 01 April 2019, the Company has adopted Ind AS 116 - "Leases" using modified approach. This has resulted in recognising right of use assets and lease liability as on 01 April 2019. The adoption of the standard did not have any material impact to the financial results.

5. During the previous year, SeQuent Antibiotics Private Limited and SeQuent Pharmaceuticals Private Limited (wholly owned subsidiaries) have applied for strike off their name from register of Registrar of Companies - Bengaluru under fast track exit scheme of Ministry of Corporate Affairs. The Registrar of Companies vide letter dated 26 July 2019 have removed their name from Register of Companies and the said companies stands dissolved. The impact of the same is immaterial in financial results.

6. The Companies Registration Office, Dublin (Republic of Ireland) vide letter dated 18 August 2019 has confirmed the strike off of Alivira UA Limited (step down foreign subsidiary). The impact of the same is immaterial in financial results.

7. With effect from 01 August 2018, the Company has acquired the EU-GMP API facility at Mahad, Maharashtra and to the extent nine months results ended 31 December 2019 is not comparable with nine months ended 31 December 2018.

8. The current tax and deferred tax expenses for the year ended 31 March 2019 include reversal of provision for tax (net of deferred tax assets) of ₹ 1,817.50 lakhs and ₹ 976.53 lakhs respectively pertaining to earlier years for subsidiary companies on completion of assessment.


9. Exports incentives are recognised based on certainty of receipt. During the quarter and nine months ended 31 December 2019, an amount of ₹ 219.10 lakhs and ₹ 498.60 lakhs respectively of export incentive income pertaining to past invoices has been recognised as attached condition of certainty is met.

10. During the quarter and nine months ended 31 December 2019, past indirect input tax credits of ₹ 303.50 lakhs is expensed out due to uncertainty in realisation of the same.

11. During the quarter, the Company has allotted 15,00,000 shares to ESOP Trust.

12. The previous period figures have been regrouped wherever necessary to conform to current period's presentation.


Place : Thane
Date : 28 January 2020



For SeQuent Scientific Limited

Manish Gupta

Manish Gupta
Managing Director



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
SeQuent Scientific Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of SeQuent Scientific Limited (the "Company") for the quarter ended December 31, 2019 and year to date from April 01, 2019 to December 31, 2019 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The comparative Ind AS financial information of the Company for the corresponding quarter and period ended December 31, 2018, included in these standalone Ind AS financial results, were reviewed by the predecessor auditor and the Ind AS standalone financial statements of the Company for the year ended March 31, 2019, was audited by predecessor auditor who expressed an unmodified opinion on that financial information and that standalone financial statements on February 01, 2019 and May 14, 2019 respectively.

For S R B C & CO LLP
Chartered Accountants

ICAI Firm registration number: 324982E/E300003

per Vikas Kumar Pansari
Partner
Membership No.: 093649UDIN: 20093649AAAAAE8339
Mumbai
January 28, 2020

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2019

(₹ in Lakhs)

	Particulars	3 months ended 31-Dec 2019	Preceding 3 months ended 30-Sep-2019	Corresponding 3 months ended in previous period 31-Dec-2018	Year to date figures for current period ended 31-Dec- 2019	Year to date figures for previous period ended 31-Dec- 2018	Previous year ended 31-Mar-19
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
I	Revenue from operations	6,179.90	5,152.00	4,814.30	16,503.90	11,066.90	16,626.00
II	Other income	211.40	719.80	302.10	1,134.30	1,194.60	1,352.50
III	Total income (I+II)	6,391.30	5,871.80	5,116.40	17,638.20	12,261.50	17,978.50
IV	Expenses						
	(a) Cost of materials consumed	2,775.05	2,531.91	2,331.20	7,860.00	5,486.50	7,733.92
	(b) Purchases of stock-in-trade	545.05	118.99	221.90	726.20	1,827.50	2,023.18
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(206.10)	93.80	3.40	91.10	(1,094.70)	(294.90)
	(d) Conversion and processing charges	1,085.40	944.90	979.80	2,924.30	2,290.10	3,180.40
	(e) Employee benefits expense	500.50	428.60	324.60	1,272.10	744.10	1,070.90
	(f) Finance costs	119.50	119.10	131.90	380.60	139.40	322.00
	(g) Depreciation and amortisation expense	219.00	222.80	229.70	664.40	495.90	722.10
	(h) Other expenses	883.70	747.50	807.30	2,443.80	1,752.90	2,600.60
	Total expenses	5,922.10	5,207.60	5,029.80	16,362.50	11,641.70	17,358.20
V	Profit before tax (III-IV)	469.20	664.20	86.60	1,275.70	619.80	620.30
VI	Tax expense/ (credits)						
	(a) Current tax	76.28	19.50	19.30	125.07	132.90	132.94
	(b) Deferred tax	101.09	(373.71)	(19.30)	(301.91)	(132.90)	(132.94)
	(c) Current tax of prior period reversed (Refer note 8)	-	-	-	-	-	(138.34)
	Total tax expenses/ (credits)	177.37	(354.21)	-	(176.84)	-	(138.34)
VII	Profit after tax (V-VI)	291.83	1,018.41	86.60	1,452.54	619.80	758.64
VIII	Other comprehensive income/ (expenses)						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurements gain / (loss) on defined benefits plans	1.10	1.10	1.70	3.30	5.10	4.40
	(b) Fair value gain / (loss) from investment in equity instruments	2,133.10	(3,423.40)	911.30	(3,571.50)	(5,192.10)	(4,217.50)
	(c) Income tax relating to items that will not be reclassified to profit or loss	(0.30)	(0.60)	-	(0.90)	-	-
	Total other comprehensive income/ (expenses) (net of tax)	2,133.90	(3,422.90)	913.00	(3,569.10)	(5,187.00)	(4,213.10)
IX	Total comprehensive income / (expenses) (VII+VIII)	2,425.73	(2,404.49)	999.60	(2,116.56)	(4,567.20)	(3,454.46)
X	Equity share capital (Face value of ₹ 2 each)	4,967.40	4,937.40	4,874.70	4,967.40	4,874.70	4,937.40
XI	Other equity						86,841.74
XII	Earnings per equity share: (Face value of ₹ 2 each) (not-annualised)						
	(1) Basic (in ₹)	0.12	0.42	0.04	0.60	0.26	0.31
	(2) Diluted (in ₹)	0.12	0.42	0.04	0.59	0.25	0.31
	See accompanying notes to unaudited standalone financial results						

**SIGNED FOR IDENTIFICATION
BY**

**S R B C & CO LLP
MUMBAI**



Notes:

- 1 The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28 January 2020. The statutory auditors have carried limited review of the above results.
- 2 The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- 3 Effective 01 April 2019, the Company has adopted Ind AS 116 - "Leases" using modified approach. This has resulted in recognising right of use assets and lease liability as on 01 April 2019. The adoption of the standard did not have any material impact to the financial results.
- 4 During the previous year, SeQuent Antibiotics Private Limited and SeQuent Pharmaceuticals Private Limited (wholly owned subsidiaries) have applied for strike off their name from register of Registrar of Companies - Bengaluru under fast track exit scheme of Ministry of Corporate Affairs. The Registrar of Companies vide letter dated 26 July 2019 have removed their name from Register of Companies and the said companies stands dissolved.
- 5 The Companies Registration Office, Dublin (Republic of Ireland) vide letter dated 18 August 2019 has confirmed the strike off of Alivira UA Limited (step down foreign subsidiary).
- 6 With effect from 01 August 2018, the Company has acquired the EU-GMP API facility at Mahad, Maharashtra and to the extent nine months results ended 31 December 2019 is not comparable with nine months ended 31 December 2018.
- 7 Exports incentives are recognised based on certainty of receipt. During the quarter and nine month ended 31 December 2019, an amount of ₹ Nil and ₹ 100.64 lakhs respectively of export incentive income pertaining to past invoices has been recognised as attached condition of certainty is met.
- 8 The current tax expenses for the year 31 March 2019 include reversal of provision of tax of ₹138.34 lakhs pertaining to earlier years on completion of assessment.
- 9 During the quarter, the Company has allotted 15,00,000 shares to ESOP Trust.
- 10 The previous period figures have been regrouped wherever necessary to conform to current period's presentation.




For SeQuent Scientific Limited

Manish
Manish Gupta
Managing Director

Place : Thane

Date: 28 January 2020



SeQuent Scientific Announces Q3 FY20 Financial Results

Q3 FY20 - EBITDA up 36% with 56% growth in PAT

9M FY20 - EBITDA up 35% with 68% growth in PAT

Mumbai, January 28, 2020

SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the quarter ended December 31, 2019.

Consolidated Financial Highlights

	Rs. in millions					
	Q3 FY20	Q3 FY19	Growth (%)	9M FY20	9M FY19	Growth (%)
Revenues	3,164	2,705	17.0%	8,787	7,574	16.0%
EBITDA	484	355	36.4%	1,247	924	34.9%
EBITDA %	15.3%	13.1%	220bps	14.2%	12.2%	200bps
PAT	203	130	55.9%	531	315	68.2%

Detailed presentation on the performance forms part of this press release.

Commenting on the Company's performance, **Manish Gupta, Managing Director** stated *"We are pleased with the financial outcome of Q3FY20, which is a good reflection of our consistent efforts towards growth and profitability. Whilst the EBITDA and PAT clocked healthy growth, we are particularly pleased that formulations has also started driving growth. The cash generation during the quarter resulted in substantial reduction in Net Debt to the tune of ~₹ 40Cr.*

We expect the momentum to continue and remain on course to meet our full year aspirations of high-teen revenue growth and 200+bps EBITDA margin expansion."

Earnings Call with Investors

The Company will conduct an Earnings call at **3:30 PM IST on January 28, 2020** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer

Tel: +91 22 4111 4717

tushar.m@sequent.in

Diwakar Pingle

Christensen Investor Relations

Tel : +91 22 4215 0210

dpingle@christensenir.com

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Websites: www.sequent.in

Abhishek Singhal

Investor Relations Consultants

abhishek.s@sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

AMBITION



EXECUTION

Earnings Presentation

Q3 & 9M FY20

January 28, 2020



Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to, "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Q3 & 9M FY20 Performance Review



Strong quarter backed by operational excellence

Revenues



₹3,164

Million

17.0%
YoY

EBITDA margin



15.3%

220bps
YoY

PAT



₹203

Million

55.9%
YoY

Cash from operations



₹465

Million

2.4x
QoQ

Industry leading growth

	Q3 FY2020		YOY	9M FY2020		YOY
Revenues	Q3 FY20	3,164	17.0%	9M FY20	8,787	16.0%
	Q3 FY19	2,705		9M FY19	7,574	
EBITDA	Q3 FY20	484	36.4%	9M FY20	1,247	34.9%
	Q3 FY19	355		9M FY19	924	
PAT	Q3 FY20	203	55.9%	9M FY20	531	68.2%
	Q3 FY19	130		9M FY19	315	

“We are pleased with the financial outcome of Q3FY20, which is a good reflection of our consistent efforts towards growth and profitability. Whilst the EBITDA and PAT clocked healthy growth, we are particularly pleased that formulations has also started driving growth. The cash generation during the quarter resulted in substantial reduction in Net Debt to the tune of ~₹ 40Cr.

We expect the momentum to continue and remain on course to meet our full year aspirations of high-teen revenue growth and 200+bps EBITDA margin expansion.”

Manish Gupta, Managing Director

Strong performance across businesses

All values in ₹ Mn

Revenue Distribution	Q3 FY20	Q3 FY19	YoY%	YoY% (Constant currency)
Formulations	2,113	1,812	16.6%	22.4%
Europe	974	946	3.0%	7.4%
Turkey	379	162	134.3%	150.3%
Emerging Markets	472	460	2.7%	5.3%
LATAM	287	245	17.3%	28.2%
APIs	1,052	893	17.7%	19.0%
Global Sales	3,164	2,705	17.0%	21.3%

9M FY20	9M FY19	YoY%	YoY% (Constant currency)
5,856	5,338	9.7%	14.9%
2,700	2,774	(2.7%)	0.8%
1,047	629	66.4%	86.7%
1,310	1,234	6.1%	7.7%
799	700	14.1%	19.3%
2,931	2,236	31.1%	30.1%
8,787	7,574	16.0%	19.4%

Key Highlights

- Global sales grew 21.3% during Q3 FY20
 - Formulations drives growth, accelerates to 22.4%
 - Strong growth across key markets of Turkey, LATAM and EU
 - APIs growth momentum continues, grows at 19.0%

Note: All growth % are in constant currency

Q3 & 9M FY20 Business Review



APIs

Scaling the
capability curve

Revenues in ₹ Mn

9M FY20	9M FY19	YoY% (cc)
2,931	2,236	30.1%

26
Commercial APIs

18
US filings/
approvals

11
CEP filings

14+
Pipeline

Highlights

- ✓ Focus on regulated markets/customers and high value products continues to drive up fixed asset turn for the business, now 2.3x
- ✓ Alivira is the # 1 Generic Animal Health USVMF Filer and # 3 Global Animal Health USVMF filer




Contribution from Top-10 products, 90%



Contribution from Top-10 customers, 56%

Alivira amongst 'Top 3' US FDA VMF Filers

US Veterinary Master File



Strategic product selection

API Filings	Competition
5	Alivira only
7	< 3 competitors
5	5+ competitors

Formulations

Value creation

Revenues in ₹ Mn

9M FY20	9M FY19	YoY% (cc)
5,856	5,338	14.9%

35+

Products Under
Development

80+

Countries with
marketing presence

1,000+

FDFs

50+%

Sales to regulated
markets

Highlights

- ✓ Regulatory headwinds completely behind in Turkey; revenue grew 86.7% in 9M
- ✓ EU reported ahead of industry growth for the quarter at 7.4%. Expect momentum to sustain going forward
- ✓ LATAM grew high-teens with both Brazil and Mexico witnessing steady growth
- ✓ Emerging markets grew by 7.7% in 9M
 - ✓ EM ex-India reported healthy double-digit growth
 - ✓ India dragged performance in EM, due to overall slowdown



Scaling value curve

API

Pipeline

US filed /
approved

EU-CEP
approvals

14+

18

10

✓ 2 US filings during the financial year

Formulations

US only
3 Products

Globally
8 Products

EU only
18 Products

- ✓ New R&D facility established in Mumbai to build regulated market pipeline
- ✓ 10 new filings in US in next 3 years
- ✓ First time capabilities established to execute Ecotoxicity and Bio Equivalence studies in India
- ✓ On-track for first US injectable filing in Q4 FY20

Filed world's largest animal injectable product in EU with an addressable global market of ~USD 350mn

R&D facility established in Mumbai



State of the Art Global infrastructure and Multifaceted Capability

- Footprint - 3,200 sq. ft
- Multi Dosage Capability – 8
 - Specialized in Injectables & Tablets
- Robust scalability - Lab to Pilot

Team

- Multidisciplinary Team of 20 scientists
100+ years of cumulative experience

Milestones



- 1st & World's largest Livestock injectable filed in EU
- Filings Planned FY21 – 4 (3 Inj., 1 tab.)

Financials

Sequent
Proven Ability In Life Sciences



Relentless Execution



Consolidated Financials


PARTICULARS	Q3 FY20 Unaudited	Q2 FY20 Unaudited	Q3 FY19 Unaudited	9M FY20 Unaudited	9M FY19 Unaudited	FY19 Audited
Revenue from Operations	3,164	2,842	2,705	8,787	7,574	10,393
Material Consumption	(1,617)	(1,508)	(1,412)	(4,557)	(3,988)	(5,430)
Gross Margin	1,547	1,335	1,293	4,230	3,586	4,963
%	48.9%	47.0%	47.8%	48.1%	47.3%	47.8%
Operating Expenses	(1,063)	(957)	(938)	(2,983)	(2,661)	(3,635)
EBITDA	484	378	355	1,247	924	1,327
%	15.3%	13.3%	13.1%	14.2%	12.2%	12.8%
Exchange Gain / (Loss)	16	(6)	2	9	(65)	(77)
Other Income	10	60	20	83	63	87
Finance Cost	(96)	(78)	(83)	(264)	(239)	(328)
Depreciation	(131)	(125)	(112)	(375)	(310)	(419)
Earnings Before Tax	283	228	182	699	373	589
Taxes	(42)	16	(26)	(61)	(17)	(20)
Earnings After Tax	241	245	156	638	356	569
Minority Interest	38	32	26	107	40	82
Earnings after Minority Interest	203	213	130	531	315	487

Key Balance Sheet items


All values in ₹ Mn

Particulars	Dec-19	Sep-19
Shareholders' funds	7,342	6,878
Minority Interest	428	401
Net Debt	2,340	2,736
Investments	1,440	1,226
Tangible Assets [#]	3,576	3,555
Intangible Assets	2,833	2,777
Working Capital	3,004	3,208

[#] Lease assets under Ind (AS) shown as Tangible assets



*9M Annualised **Adjusted for investments



Highlights
- Operating leverage drives ROCEs higher - Net Debt to EBITDA declines to 1.41x, adjusted for investments at 0.55x - Net Working Capital days improves by 15 days - Strong cash flow generation of ₹465Mn brings down net debt

FY20 Outlook

Sequent
Proven Ability In Life Sciences



Remain confident on achieving FY20 outlook



FY20 Outlook

- High-teen revenue growth
- 200+ bps margin expansion



9M FY20 status

- 16.0% revenue growth
- 200 bps margin expansion



Thank You

SeQuent Scientific Limited

CIN: L99999MH1985PLC036685

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra
Tel No: +91 22 4111 4777 | Website: www.sequent.in | E-mail id: info@sequent.in



For details, feel free to contact:

Tushar Mistry

Chief Financial Officer

+91 22 4111 4717

✉ tushar.m@sequent.in

Diwakar Pingle

Christensen Investor Relations

+91 22 4215 0210

✉ dpingle@christensenir.com

Abhishek Singhal

Investor Relations Consultant

✉ abhishek.s@sequent.in

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

Websites: www.sequent.in, www.alivira.co | CIN: L99999MH1985PLC036685 | BSE Code:512529 | NSE: SEQUENT | ISIN: INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

